BioRestorative TherapiesBRTX
BRTX
About: BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Employees: 11
0
Funds holding %
of 7,345 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
24% more capital invested
Capital invested by funds: $406K [Q4 2024] → $502K (+$96.2K) [Q1 2025]
0.02% less ownership
Funds ownership: 4.1% [Q4 2024] → 4.07% (-0.02%) [Q1 2025]
7% less funds holding
Funds holding: 15 [Q4 2024] → 14 (-1) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for BRTX.
Financial journalist opinion
Based on 3 articles about BRTX published over the past 30 days
Neutral
Seeking Alpha
1 day ago
BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Francisco J. Silva - VP of Research & Development, Secretary and Director Lance Alstodt - Chairman of the Board, President & CEO Robert Eugene Kristal - Chief Financial Officer Stephen Kilmer - Investor Relations Officer Conference Call Participants Jonathan Matthew Aschoff - ROTH Capital Partners, LLC, Research Division Michael Okunewitch - Maxim Group LLC, Research Division Operator Greetings.
Neutral
Zacks Investment Research
1 day ago
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.5 per share a year ago.
Neutral
GlobeNewsWire
1 week ago
BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.
Neutral
GlobeNewsWire
1 month ago
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates
MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time.
Neutral
GlobeNewsWire
1 month ago
BioRestorative Announces Share Repurchase Program
MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $2 million of its outstanding common stock through June 16, 2026.
Neutral
GlobeNewsWire
2 months ago
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
– The International Society for Stem Cell Research (“ISSCR”) 2025 Annual Meeting is the world's foremost gathering of stem cell and regenerative medicine leaders –
Neutral
GlobeNewsWire
2 months ago
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
– New blinded safety and efficacy data from 30 patients in ongoing Phase 2 trial to be unveiled June 13, 2025 – – ISSCR 2025 is the premier global event for stem cell research, drawing nearly 4,000 leaders from academia, biotech, and pharma – – BioRestorative to release new clinical data to the public prior to market open on June 13th – MELVILLE, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced that new preliminary, blinded clinical data from 30 patients enrolled in its ongoing Phase 2 trial of BRTX-100 for the treatment of chronic lumbar disc disease (cLDD) will be presented at the prestigious International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, held June 11–14, 2025, in Hong Kong.
Neutral
Seeking Alpha
3 months ago
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
BioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q1 2025 Earnings Call May 14, 2025 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Lance Alstodt - Chairman and Chief Executive Officer Francisco Silva - Vice President, Research and Development Robert Kristal - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Jason McCarthy - Maxim Group Operator Good afternoon, everyone and welcome to the BioRestorative Therapies First Quarter 2025 Investor Call. [Operator Instructions] Please note, this conference is being recorded.
Negative
Zacks Investment Research
3 months ago
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
MELVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that preliminary 26-, 52- and 104-week blinded preliminary data from the first 15 patients with chronic lumbar disc disease (“cLDD”) enrolled in the ongoing Phase 2 clinical trial of BRTX-100 was recently presented by Francisco Silva, Vice President of Research and Development, at the International Society for Cell & Gene Therapy (“ISCT”) 2025 Annual Meeting.
Charts implemented using Lightweight Charts™